Rizatriptan Benzoate Tablet
Product Images NDC 29300-317

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 29300-317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 01

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 02

Db8f9f09 0af5 4528 A7af 831c2d861375 02
The text describes a graph showing the estimated probability of response to different doses of Rizatriptan Benzoate Tablets, USP. The graph shows the probability of response at different time intervals post-dose. Unfortunately, there is no additional information to give a more detailed description.*
FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 03

Db8f9f09 0af5 4528 A7af 831c2d861375 03
This text seems to be a table showing the percentage levels of different components (possibly medications) over the course of 24 hours post-dose. It contains some chemical names and dosages and may be related to a medical study or prescription instructions.*
FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 04

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 05

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 06

Db8f9f09 0af5 4528 A7af 831c2d861375 06
This appears to be a chart or graph related to the effectiveness of Rizatriptan Benzoate Orally Disintegrating Tablets compared to a placebo. The x-axis seems to represent the time elapsed (in hours) after taking the medication, while the y-axis is not visible in the provided text. The title of the chart appears to be "Percent (35% C1)" and it shows data points for both the medication and the placebo at various time intervals. Without more information, it is unclear what the 35% C1 refers to.*
FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 07

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 08

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 09

FDA Label Image

Db8f9f09 0af5 4528 A7af 831c2d861375 10

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.